Neurogene is a pharmaceutical company that develops and commercializes genetic medicines for the treatment of neurological diseases.
$200M
Nov 03, 2024
-
Inventiva is a France-based biopharmaceutical company that researches and develops oral small-molecule therapies for the treatment of lysosomal storage disorders.
$102.9M
Oct 13, 2024
-
Cellipont is a California-based CDMO that offers services such as cell therapy development and clinical trials for the pharmaceutical and biotechnology industries.
-
Oct 06, 2024
-
Context Therapeutics is a Pennsylvania-based biopharmaceutical company that researches and develops novel therapies for the treatment of solid tumors.
$100M
May 05, 2024
-
Outlook Therapeutics is a New Jersey-based biopharmaceutical company that researches and develops bevacizumab-based medicinal drugs for the treatment of retinal diseases.
$159M
Mar 17, 2024
-
Frequently Asked Questions about Great Point Partners
What is Great Point Partners investing in?
Great Point Partners has invested in 31 companies including Neurogene, Inventiva and Cellipont
What company did Great Point Partners invest in?
Great Point Partners invested in a total 31 companies including Neurogene, Inventiva and Cellipont
What are the top 5 investments by Great Point Partners?
The top companies in which Great Point Partners invested are Neurogene, Inventiva, Cellipont, Context Therapeutics and Outlook Therapeutics
